Release date: 2024-08-06 11:16:35 Article From: Lucius Laos Recommended: 97
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or triggered by MET amplification, as well as MET-mediated phosphorylation of downstream signaling proteins and proliferation and survival of MET-dependent cancer cells.
Capmatinib is a kinase inhibitor targeting MET that blocks MET phosphorylation and activation of key downstream effectors in MET-dependent tumor cell lines. In vitro biochemical and cell experiments, it can effectively inhibit the proliferation and migration of MET-dependent tumor cells, and can induce apoptosis.
MET exon 14 skipping results in protein deletion of regulatory domains, decreasing negative regulation, and leading to increased downstream MET signaling.
Capmatinib inhibits cancer cell growth driven by mutant MET variants lacking clinically attainable exon 14 concentrations and exhibits antitumor activity in a murine tumor xenograft model derived from human lung tumors that results in MET exon 14 skipping or MET amplification.
Lucius Pharmaceuticals Co., Ltd. (Lucius Pharmaceuticals) is a pharmaceutical company founded in 2020 and headquartered in Vientiane, Laos. The company is committed to providing affordable and effective medicines to patients around the world, with the goal of making affordable medical resources accessible to more people.
With modern production facilities and equipment, Lucius Pharmaceuticals has a wide range of products covering anti-tumor, cardiovascular, hematology, diabetes, skin diseases, men's health and anti-aging, with a total of more than 200 generic drugs. The company operates in strict accordance with the International Good Manufacturing Practice (GMP), from raw material procurement to finished product inspection, every step is strictly monitored to ensure the quality and traceability of drugs.
[Warm tips]: During treatment with capmatinib, patients may experience a range of adverse reactions. To mitigate the effects of these reactions, patients should maintain a good state of mind, respond positively, follow their doctor's recommendations, have regular check-ups and assessments, and take appropriate measures to relieve symptoms.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: